Huixinyigu raised tens of millions of CNY through the angel round of funding. Green Pine Capital Partners was the sole backer of the round. The money will go toward team building, research, and an IND application.
Huixinyigu, founded in 2021, is a cutting-edge biopharmaceutical company specializing in cell therapy for neurological diseases. Its factory in company Beijing Zhongguancun was officially opened in March 2022, and research for drug clinical trial applications is being conducted at the same time.
Huixin treats Parkinson's disease by directly inducing neural stem cells (iNSCs) from peripheral blood mononuclear cells or fibroblasts and differentiating them into dopaminergic neural precursor cells (iNSC-DAP) using cutting-edge reprogramming technology and a non-integrated system. According to reports, this technology does not use induced pluripotent stem cells.
iNSCs are created using somatic cell reprogramming, said Professor Zhiguo Chen, the founder of Huixin. They have the same ability to self-renew and differentiate as neural stem cells. This type of cell, on the other hand, is less likely to cause cancer and thus less dangerous. It also has a large number of sources and the ability to differentiate into specific nerve cells quickly. It can also be used for autologous or allogeneic transplantation, potentially changing the current clinical situation of Parkinson's disease and other neurological diseases with no effective treatments, especially for long-term patients.